Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $24.25.
ANL has been the topic of several recent research reports. Oppenheimer initiated coverage on Adlai Nortye in a report on Thursday, May 28th. They set an “outperform” rating and a $32.00 target price on the stock. Wall Street Zen upgraded Adlai Nortye to a “hold” rating in a report on Saturday, March 7th. JonesTrading initiated coverage on Adlai Nortye in a report on Thursday, May 14th. They set a “buy” rating and a $22.00 target price on the stock. Leerink Partners initiated coverage on Adlai Nortye in a report on Friday, March 20th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, HC Wainwright raised their target price on Adlai Nortye from $16.00 to $20.00 and gave the company a “buy” rating in a report on Monday, April 20th.
Check Out Our Latest Stock Report on Adlai Nortye
Adlai Nortye Stock Performance
Hedge Funds Weigh In On Adlai Nortye
Several institutional investors have recently bought and sold shares of ANL. Renaissance Technologies LLC bought a new position in shares of Adlai Nortye in the first quarter worth about $457,000. ADAR1 Capital Management LLC bought a new position in shares of Adlai Nortye in the first quarter worth about $816,000. Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye in the first quarter worth about $1,140,000. Finally, SmartHarvest Portfolios LLC increased its stake in shares of Adlai Nortye by 8.5% in the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock worth $113,000 after purchasing an additional 1,279 shares during the period. 35.21% of the stock is currently owned by institutional investors.
Adlai Nortye Company Profile
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Recommended Stories
- Five stocks we like better than Adlai Nortye
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
